ORPHA:251656
Oligoastrocytoma, dual genotype
Also known as: MOA · Mixed oligoastrocytoma · Oligoastrocytoma, dual genotype NEC · Oligoastrocytoma, dual genotype, not elsewhere classified
Publications
5,641
Trials
63
Interventional, condition-specific
Researchers
1,221
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Oligoastrocytoma is a type of low-grade glioma with a mixed astrocytoma and oligodendroglioma histology, manifesting with headaches, speech and motor problems, and, in some, subarachnoid haemorrhage.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016702
- UMLS:C0547065
- NCIT:C4050
Additional Mondo synonyms (10)
WHO grade II mixed glioma · glioma, mixed, benign · mixed astrocytic-oligodendroglial neoplasm · mixed astrocytic-oligodendroglial tumor · mixed astrocytic-oligodendroglial tumour · mixed astrocytoma-oligodendroglioma · mixed oligo-astrocytoma · mixed oligoastrocytoma · mixed oligodendroglioma-astrocytoma · oligoastrocytoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
5,641 matched papers (2,974 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
63 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
16
Drugs / clinical candidates · MONDO_0016702
- CHLOROTOXIN·phase 2
- FILGRASTIM·phase 2
- IMATINIB MESYLATE·phase 2
- LOMUSTINE·phase 2
- PALBOCICLIB·phase 2
- PROCARBAZINE HYDROCHLORIDE·phase 2
- SARGRAMOSTIM·phase 2
- TEMOZOLOMIDE·phase 2
- THIOTEPA·phase 2
- VINCRISTINE SULFATE·phase 2
- HILTONOL·phase 1
- CARBOPLATIN·phase 1 2
- ETOPOSIDE PHOSPHATE·phase 1 2
- MANNITOL·phase 1 2
- MELPHALAN·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
5,641
5,641 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
5,641 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,974 in the last 10 years · low confidence
Phrase hits: 5,641 · MeSH hits: 0
Who's working on it?
1,221
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Liu J5 papers · 2026
School of Ocean and Earth Science, Tongji University, Shanghai, China.
Papers in Europe PMC - 02Zhu J5 papers · 2025
The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Papers in Europe PMC - 03Chen L4 papers · 2025
Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Lu Zhou, China.
Papers in Europe PMC - 04Lee H4 papers · 2023
Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.
Papers in Europe PMC - 05Li S4 papers · 2026
Department of Genetic Testing Center, The First Affiliated Hospital of Dali University, Dali, China.
Papers in Europe PMC - 06Li Y4 papers · 2026
Hunan Provincial Key Laboratory of Animal Intestinal Function and Regulation, School of Life Sciences, Hunan Normal University, Changsha, Hunan, China.
Papers in Europe PMC - 07Zhang L4 papers · 2026
Institute of Molecular Medicine, Department of Preventive Medicine, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Academy for Advanced Interdisciplinary Studies, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China.
Papers in Europe PMC - 08Zhang Y4 papers · 2026
Department of Genetic Testing Center, The First Affiliated Hospital of Dali University, Dali, China.
Papers in Europe PMC - 09
- 10Chen Y3 papers · 2025
1Graduate School, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
63
interventional trials for this specific condition
63 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026
63 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97.7th percentile).
low confidence · 97.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
63 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04623931·RECRUITING·Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Not reviewed·Conditions: Anaplastic Astrocytoma, IDH-Wildtype · Anaplastic Oligoastrocytoma · Anaplastic Oligodendroglioma · Diffuse Astrocytoma, IDH-Wildtype·Matched via name phrase
- NCT02800486·RECRUITING·Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Not reviewed·Conditions: Glioblastoma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Glioma·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Oligoastrocytoma, dual genotype — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Oligoastrocytoma, dual genotype" OR "Mixed oligoastrocytoma" OR "Oligoastrocytoma, dual genotype NEC" OR "Oligoastrocytoma, dual genotype, not elsewhere classified" OR "WHO grade II mixed glioma" OR "glioma, mixed, benign" OR "mixed astrocytic-oligodendroglial neoplasm" OR "mixed astrocytic-oligodendroglial tumor" OR "mixed astrocytic-oligodendroglial tumour" OR "mixed astrocytoma-oligodendroglioma" OR "mixed oligo-astrocytoma" OR "mixed oligodendroglioma-astrocytoma" OR "oligoastrocytoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Oligoastrocytoma, dual genotype" OR "Mixed oligoastrocytoma" OR "Oligoastrocytoma, dual genotype NEC" OR "Oligoastrocytoma, dual genotype, not elsewhere classified" OR "WHO grade II mixed glioma" OR "glioma, mixed, benign" OR "mixed astrocytic-oligodendroglial neoplasm" OR "mixed astrocytic-oligodendroglial tumor" OR "mixed astrocytic-oligodendroglial tumour" OR "mixed astrocytoma-oligodendroglioma" OR "mixed oligo-astrocytoma" OR "mixed oligodendroglioma-astrocytoma" OR "oligoastrocytoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 63 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MOA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (5641) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T10:51:36.532Z